nun auch aastrom - 500 Beiträge pro Seite

[1999]

nachdem in den vergangenen tagen Cephaid, Siga Tech, Bruker Daltonic und Amer Acces zu teil fulminante kurssprünge vollzogen haben, scheint jetzt auch Aastrom (dt. share 905286) anzuspringen.

meiner meinung nach immer noch einer der interessantesten biotech-titel. (auch ohne "terror-fantasie") --> www.aastrom.com einfach mal anschauen.

gute geschäfte,
1999

[t.1]

@1999
ja das wird wohl stimmen was du geschrieben hast.aastrom ist billig und hat eine tolle pipline von produkten bzw schon in europa auf dem markt zu haben.

[t.1]

Aastrom Biosciences Announces CE Mark Approval For First Dendritic Cell Therapy Product in Europe
10/2/01



- Dendritic Cell Vaccines Offer New Therapy Options for Cancer Patients -

ANN ARBOR, Mich., Oct 2, 2001 /PRNewswire via COMTEX/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM), today announced that it has obtained approval to affix the CE Mark to the DC-I Cell Therapy Kit for the ex vivo production of human dendritic cells, allowing the Company to market and sell the product in Europe. The DC-I product is used to produce Aastrom`s innovative proprietary dendritic cell product, the Dendricell(TM), that is intended to provide a base dendritic cell for a broad range of cancer vaccines being developed using cancer-associated antigens.
The DC-I dendritic cell production product utilizes Aastrom`s patented single-pass perfusion methodology, for enhanced cell biology and outcome reliability in the production of clinical quantities of dendritic cells. Additionally, the DC-I dendritic cell product is produced in the AastromReplicell(TM) System platform, enabling the automated, process-controlled cell production of human dendritic cells in compliance with regulatory requirements for Good Manufacturing Practice (GMP).

"Dendritic cell vaccines are aggressively being explored in the European clinical community," commented Holger Beckmann, Managing Director of Zellera AG, Aastrom`s European subsidiary. "In conjunction with the excellent biological activity of the Dendricell(TM), Aastrom`s DC-I product automation addresses a clear need for GMP-compliant dendritic cell production capability, aiding the customers in meeting requirements of European regulatory agencies."

This announcement follows earlier approvals received by Aastrom to affix the CE Mark to the AastromReplicell(TM) System instrumentation platform, and the SC-I bone marrow and CB-I cord blood cell production products used for stem cell therapies. These developments have helped Aastrom secure an industry-leading position using cells for therapeutic procedures.

Earlier this year Aastrom announced the initiation of external clinical beta site evaluations of the DC-I dendritic cell product at the Barbara Ann Karmanos Cancer Institute at Wayne State University (Detroit, MI), Beth Israel Deaconess Medical Center (Boston, MA), the Universitatsklinikum Charite (Berlin, Germany), and the University of Gottingen (Gottingen, Germany). Successful validation of the DC-I cell product by external sites demonstrates that Aastrom`s process performance is transferable and reproducible by external laboratories, and is a part of Aastrom`s quality system requirement for CE Marking.

"This significant milestone broadens Aastrom`s product and market opportunities beyond our previous stem cell therapy focus," said R. Douglas Armstrong, Ph.D., President and Chief Executive Officer of Aastrom. "Most experts recognize the therapeutic potential of dendritic cell vaccines, but have not had the technology needed to provide an accessible, biologically robust, dendritic cell supply. Aastrom is meeting this market need by applying its proprietary cell culture capabilities to produce novel cell therapeutics in a practical approach."

About Zellera AG

Zellera AG is a wholly-owned subsidiary of Aastrom Biosciences, Inc., located in Berlin, Germany. Zellera serves as the sales and marketing operational base for Aastrom`s products in Europe.

About Aastrom Biosciences, Inc.

Aastrom (http://www.aastrom.com) is a leader in the development of proprietary cell therapeutic products based on its dual-technology platforms: patented "single-pass perfusion" providing cells with enhanced biological function, and patented GMP-compliant system automation facilitating the delivery of cells for therapeutic use into medical practice. These technologies are integrated into the AastromReplicell(TM) System that is designed to uniquely standardize and automate the processes involved in producing high quality therapeutic cells. Aastrom is developing a range of cell therapeutic products including, the Dendricell(TM) products for use in the dendritic cell-based cancer vaccine market, and the OC-I bone progenitor cell product for the treatment of degenerative bone diseases such as osteoporosis. The AastromReplicell(TM) System, the SC-I bone marrow and the CB-I cord blood cell production products have previously received CE Mark approval necessary for European marketing and are in late-stage U.S. clinical trials. These products are not available for sale at this time in the U.S., except for research or investigational use.

This document contains forward-looking statements, including without limitation, statements regarding product development objectives, clinical trial results, potential product applications and potential advantages of the AastromReplicell(TM) System and related cell therapy kits, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "intend," "potential," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the results obtained from clinical trial and development activities, research activities being conducted by others, regulatory approval requirements, the availability of resources, competitive developments and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom`s Annual Report on Form-10K, and other filings with the Securities and Exchange Commission.



Kris M. Maly Noonan/Russo Communications, Inc.
Investor Relations Manager Phone: [phone]
Aastrom Biosciences, Inc. Glenn Silver, ext. 271 (media)
Phone: [phone] David Walsey, ext. 230 (investors)

Holger Beckmann
Managing Director
Zellera AG
Berlin, Germany
Phone: 49-30-2065-9165

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X04781855
SOURCE Aastrom Biosciences, Inc.
(C) 2001 PR Newswire. All rights reserved.

News provided by Comtex

© 2000 StockHouse.com | Disclaimer

[1999]

eben. die anderen o.g. werte mögen zwar auch "gut" sein (soweit ich das überhaupt beurteilen kann), jedoch sind kursaufschläge wie in den letzten tagen wohl kaum zu rechtfertigen. das ist absolute übertreibung...

mit Aastrom legt man sich einen wert in`s depot, der wenigstens schon "etwas" an substanz zu bieten hat und dafür noch recht günstig zu haben ist.

gruß,
1999

[t.1]

@1999
wenn es dir aufgefallen sein sollte,steigt aastrom mit stemcell um einen tag verzögert.das bedeuted für den 11.10.2001 gute kurssteigerung.
grüße t.1

[1999]

ist ja `ne gewagte these aber ich denke mal, Stemcells lockt schon viel mehr trader allein mit dem namen an... S T E M C E L L S hmmm, ..das hört sich doch schon gleich richtig gut an.

naja, wir werden sehen. im moment ist Aastrom bei uns jedenfalls rund 5% billiger zu haben als im Amiland. kurs 1,24 € in Berlin, das wären also 1,13 $. Nasdaq-kurs ist 1,18 $.

gruß,
1999

[1999]

leute leute leute!

dat sieht ja furchtbar aus, bei Aastrom! heute gerade mal 1.395 (!) stücke gehandelt...

gibt es hier noch ein paar gleichgesinnte oder bin ich der letzte, der diese teile noch hat??

schönes we,
1999

[Junkers87DStuka]

im jahre 2000 hatte ich das Ding auch, war eine geile zeit damals



auch mit Nexel Therapeutics